Palmitat de paliperidona trimestral: tractament de manteniment de l'esquizofrènia en pacients adults clínicament estables amb la formulació injectable mensual de palmitat de paliperidona
Abstract
Paliperidone palmitato trimestral is the first commercialized quarterly administration antipsychotic. Although the actual benefit on adherence is unknown, the use of this medication may be adequate for patients stabilized with the monthly formulation of paliperidone preferably for a period of more than 4 months, to reduce the number of patients, Administrations and the pharmacological cost. The change in the monthly administration interval from quarter to year should not involve modifications in the patient's clinical follow-up
Keywords
Atypical antipsychotics; Depot shape; Prolonged release
Bibliographic citation
Palmitat de paliperidona trimestral: tractament de manteniment de l'esquizofrènia en pacients adults clínicament estables amb la formulació injectable mensual de palmitat de paliperidona. Barcelona: Servei Català de la Salut; 2017.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3505This item appears in following collections
The following license files are associated with this item: